PT Diastika Biotekindo (CHEK), a seasoned player in Indonesia’s medical equipment distribution industry, is set to debut on the Indonesia Stock Exchange (IDX) on July 10, 2025.
Through its initial public offering (IPO), CHEK will release up to 815 million new shares, representing 20.04 percent of its post-IPO issued capital, with a price range of Rp120 to Rp140 per share.
The company aims to raise as much as Rp114.1 billion (US$7 million) from the offering. All proceeds from the IPO will be allocated to working capital, specifically for the procurement of merchandise and operational expenses.
Established in 1989, CHEK has a long history in the Indonesian medical equipment sector, working with global principals like Bio-Rad and Thermo Fisher. Through its IPO, the company seeks to solidify its market presence and expand participation in government procurement programs, including SIHREN, SOPHI, and InPLUS, coordinated by the Ministry of Health.
CHEK shares ownership ties with fellow IDX-listed medical supplier PT UBC Medical Indonesia Tbk (LABS). Both companies are majority-owned by PT Optel Investama Mulia, which holds 76.54 percent of CHEK and 72.39 percent of LABS. The two companies are also supported by the same underwriter, Lotus Sekuritas.
According to CHEK’s prospectus, the company is a joint venture linked to Chinese pharmaceutical magnate Lam Kong, via the Cayman Islands-based Hope Fortune Investment Ltd, which fully owns Active Rich Investment Limited− a stakeholder in Optel Investama. Optel is also active in investment consultancy and pharmaceutical trading.
Optel Investama’s shareholders include:
● Laurentia Hariadi – 32.67 percent;
● Karjeny Satia – 17.82 percent;
● Active Rich Investment Limited – 16.40 percent;
● Healthy Alliance Limited – stake undisclosed.
Other shareholders include Ave Nina Sutikno, Nathan Tirtana, Venny Haryanti, Zhou Biyan, and treasury stock under Optel’s name.
Laurentia Hariadi, wife of LABS’ controlling shareholder Nathan Tirtana, has been officially designated as CHEK’s controller, in line with OJK Regulation No. 3/2021. Her controlling position must remain unchanged for at least 12 months post-IPO effective date.
Leadership structure
Board of Directors:
● President Director: Nathan Tirtana;
● Director: Qi Fei;
● Director: Franciscus Xaverius Yoshua Raintjung.
Board of Commissioners:
● President Commissioner: Ave Nina Sutikno;
● Commissioner: Hong Tan.
Nathan Tirtana, a University of New South Wales engineering graduate (2002), brings years of biotech experience, having served as a senior executive at Shanghai United Cell Biotechnology Co., Ltd from 2003 to 2024. He also served as commissioner of PT Inodia, a shareholder in LABS, from 2010 to 2012.
Already have an account? Sign In
-
Start reading
Freemium
-
Monthly Subscription
20% OFF$29.75
$37.19/MonthCancel anytime
This offer is open to all new subscribers!
Subscribe now -
Yearly Subscription
33% OFF$228.13
$340.5/YearCancel anytime
This offer is open to all new subscribers!
Subscribe now
Set up email notifications for these topics
